The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A pharmacodynamic study of JI-101, an orally active inhibitor of VEGF-2, PDGF-β, and EphB4 receptors, in patients with refractory/recurrent ovarian cancer.
Theresa Louise Werner
Research Funding - Vanthys
Aaron Lynn Luebke
No relevant relationships to disclose
Mark Wade
No relevant relationships to disclose
Nuggehally R Srinivas
Employment or Leadership Position - Vanthys
Consultant or Advisory Role - Vanthys
Dhiraj J. Abhyankar
Employment or Leadership Position - Vanthys
Consultant or Advisory Role - Vanthys
Philip Caligiuri
No relevant relationships to disclose
Marta Elise Heilbrun
No relevant relationships to disclose
Sunil Sharma
Research Funding - Jubilant Pharmaceuticals; Vanthys